ZMC(SH:600216)2022-04-26 16:00Financial Performance - The net profit attributable to the parent company's shareholders for 2021 was CNY 1,045,319,896.03, while the net profit for the parent company was CNY 1,458,646,166.63[7] - The company achieved operating revenue of 9,129,094,496.62 RMB in 2021, representing a year-on-year increase of 24.60%[24] - The net profit attributable to shareholders of the listed company was 1,045,319,896.03 RMB, an increase of 45.71% compared to the previous year[24] - The net profit after deducting non-recurring gains and losses was 982,333,727.83 RMB, reflecting a growth of 67.44% year-on-year[24] - The company's total assets reached 12,531,979,840.23 RMB at the end of 2021, up 19.35% from the end of 2020[24] - The basic earnings per share for 2021 was 1.09 RMB, a 45.33% increase from 0.75 RMB in 2020[24] - The weighted average return on equity increased to 12.64%, up 3.38 percentage points from the previous year[24] - The company reported a net cash flow from operating activities of 1,136,655,957.52 RMB, a decrease of 9.55% compared to 2020[24] - The total revenue reached ¥9,087,790,708.10, with a year-on-year increase of 24.59%[60] - The company reported a gross margin of 41.13% for total operations, a decrease of 0.60 percentage points compared to last year[60] Dividend and Earnings Distribution - The company plans to distribute a cash dividend of CNY 3.30 per 10 shares, totaling CNY 318,492,240.00, based on a total share capital of 96,512,800 shares as of April 26, 2022[7] - The retained earnings available for distribution to shareholders at the end of the period amounted to CNY 5,627,858,012.02 after accounting for the legal surplus reserve[7] Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[11] - The company has outlined potential risks and countermeasures in its future operations in the management discussion section[11] - The company has confirmed that there were no non-operating fund occupations by controlling shareholders or related parties[9] - The company has maintained compliance with decision-making procedures regarding external guarantees[9] Audit and Compliance - The report includes a standard unqualified audit opinion from Tianjian Accounting Firm[6] - The company has maintained a focus on supply chain stability and structural reforms amid challenges from the pandemic and rising raw material prices[33] Research and Development - The company has applied for 19 invention patents during the reporting period, with 17 domestic and 3 international patents granted, bringing the total to 663 applied and 273 effective patents as of December 2021[39] - The company is focusing on the development of biopharmaceuticals and aims to transition from a traditional pharmaceutical company to a leading global pharmaceutical enterprise[99] - The company is investing in research and development for new formulations and delivery methods for existing products, aiming to improve efficacy and patient compliance[110] - The company has a strong pipeline of new products, including innovative formulations for existing drugs, which are expected to drive future growth[110] Product Development and Market Expansion - The company has successfully passed the consistency evaluation for its injectable drugs, including Teicoplanin (0.2g) and Vancomycin (0.5g), and received drug registration certificates for several products, including Sitagliptin Phosphate Tablets (100mg, 50mg) and Levofloxacin Tablets (0.5g, 0.25g)[35] - The company has made significant progress in its ADC innovative drug projects, with the clinical trials for ARX788 for breast cancer nearing completion and ongoing trials for gastric cancer[38] - The company is actively pursuing new product development and has completed the optimization of the formulation process for Daptomycin[38] - The company is exploring opportunities for market expansion and potential acquisitions to enhance its competitive position in the pharmaceutical industry[110] Sales and Revenue Breakdown - The company's sales revenue for life nutrition products reached CNY 473.66 million, accounting for 51.89% of total revenue, with a year-on-year growth of 44.23%[55] - Pharmaceutical manufacturing achieved sales of CNY 207.85 million, representing 22.77% of total revenue, with a year-on-year increase of 2.04%[55] - The pharmaceutical commercial segment generated sales of CNY 224.88 million, making up 24.63% of total revenue, with a year-on-year growth of 14.50%[55] Cost and Expense Management - Operating costs rose to CNY 5.40 billion, reflecting a 26.06% increase compared to CNY 4.28 billion last year[57] - Research and development expenses increased by 47.75% to CNY 806.86 million, up from CNY 546.09 million[57] - The company reported a significant increase in non-current liabilities due within one year, rising to ¥450,495,000, a 125.06% increase compared to ¥200,165,000 in the previous period[14] Corporate Governance and Management Changes - The total pre-tax compensation for the board members and senior management during the reporting period amounted to ¥2,289.50 million[180] - The company has undergone significant changes in its board and management personnel, with multiple elections and appointments during the reporting period[199] - The company is committed to transparency in its remuneration policies, ensuring they are aligned with shareholder interests[198] Future Outlook and Strategic Goals - The company aims for a revenue target of 9.0 billion yuan and a profit target of 560 million yuan for 2022, acknowledging the uncertainty in achieving these goals due to external factors[164] - The company plans to enhance its product offerings in the fields of fat-soluble vitamins, polyunsaturated fatty acids, and carotenoids, while also entering the spice and food sectors[160] - The company is focusing on expanding its antibiotic product line, with significant sales volumes reported across various antibiotic categories[115]